10-K: Curis Faces Going Concern Doubt Amid Emavusertib Development

Curis, Inc. reported a net loss of $7.6 million for 2025 and raised substantial doubt about its ability to continue as a going concern, despite recent financing and ongoing clinical trials for its lead drug candidate, emavusertib.

Summary

• The company is a biotechnology firm focused on developing emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and FLT3, for cancer treatment.
• Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study for relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with ibrutinib.
• A Phase 2 combination study of emavusertib in chronic lymphocytic leukemia (CLL) with zanubrutinib, known as TakeAim CLL, was recently initiated, with dosing expected in the first half of 2026 and initial data in Q4 2026.
• Monotherapy and combination studies of emavusertib in AML are substantially complete, with plans for continued development contingent on additional funding.
• Emavusertib has received Orphan Drug Designation from the U.S. FDA for PCNSL, AML, and MDS, and from the European Commission for PCNSL.
• Productive meetings with the European Committee for Medicinal Products for Human Use (CHMP) and the FDA in March 2025 indicated potential for accelerated regulatory paths for emavusertib in PCNSL, subject to specific data requirements.
• The company reported a net loss of $7.6 million for the year ended December 31, 2025, which includes a one-time non-cash gain of $27.2 million from the sale of future royalties.
• As of December 31, 2025, cash and cash equivalents were $5.1 million, and the accumulated deficit was $1.2 billion.
• In January 2026, the company completed a private placement (PIPE Financing) for net proceeds of approximately $18.6 million.
• The company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern beyond 12 months from the filing date.
• In November 2025, the company sold its 100% interest in Curis Royalty, including the Erivedge intellectual property and the Genentech License Agreement, for $2.5 million upfront and a release of liability related to the sale of future royalties. The company is no longer entitled to revenues under the Genentech License Agreement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging financial position, primarily due to the 'going concern' doubt and the need for substantial future capital, despite some positive clinical and financing updates.

Positives

• Emavusertib has received Orphan Drug Designation from the U.S. FDA for PCNSL, AML, and MDS, and from the European Commission for PCNSL, which may provide regulatory incentives and market exclusivity.
• Productive meetings with the CHMP and FDA in March 2025 suggest a potential accelerated regulatory path for emavusertib in PCNSL, indicating a possible faster route to market.
• The company successfully completed a January 2026 PIPE Financing, raising approximately $18.6 million in net proceeds, providing some immediate capital.
• Net loss significantly decreased to $7.6 million in 2025 from $43.4 million in 2024, largely due to a non-cash gain of $27.2 million from the sale of Erivedge royalty rights.
• Research and development expenses decreased by 27% to $28.3 million in 2025, and general and administrative expenses decreased by 16% to $14.0 million, reflecting cost management efforts.
• The company regained compliance with Nasdaq's Minimum Market Value of Listed Securities (MVLS) Requirement as of February 3, 2026.

Negatives

• The company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern beyond the next 12 months from the filing date.
• An accumulated deficit of $1.2 billion as of December 31, 2025, highlights a history of significant losses.
• The company will require substantial additional capital to fund the development of emavusertib through regulatory approval and commercialization, and expects to face substantial difficulties in raising this capital.
• The sale of Erivedge royalty rights in November 2025 means the company is no longer entitled to revenues from the Genentech License Agreement, eliminating a previous revenue stream.
• Emavusertib is still in early clinical development, and its therapeutic efficacy in humans is unproven, carrying inherent risks of failure.
• The company has never obtained marketing approval for a drug candidate, indicating a lack of commercialization experience.
• Heavy reliance on third parties for clinical trials and manufacturing introduces risks related to performance, compliance, and supply chain disruptions.
• The company faces substantial competition from larger pharmaceutical and biotechnology companies with greater resources and experience.

Risks

• Heavy dependence on the success of emavusertib, which is in early clinical development and may not be successful, leading to material harm if commercialization is delayed or fails.
• Identified conditions and events raise substantial doubt about the company's ability to continue as a going concern.
• Incurred substantial losses since inception, expect to continue incurring losses, and may never generate significant revenue or achieve profitability.
• Will require substantial additional capital, and inability to raise funds could force delays, reductions, or elimination of drug development or commercialization efforts, adversely affecting operations.
• Inability to obtain, or delays in obtaining, marketing approval for emavusertib or future drug candidates, as the company has never obtained such approval.
• Potential failure to establish additional strategic collaborations, which could adversely affect the ability to develop and commercialize emavusertib.
• Reliance on third parties to conduct clinical trials; inadequate performance or failure to meet deadlines by these parties could hinder development and commercialization.
• The marketing approval process is expensive, time-consuming, and uncertain, potentially preventing or delaying commercialization.
• Substantial competition from companies with greater financial, R&D, manufacturing, and marketing capabilities.
• Inability to obtain and maintain patent protection for technologies and drugs, or reliance on licensors for patent protection that may be insufficient.
• Failure to attract and retain key management and scientific personnel and advisors could impede business objectives.
• Risk of delisting from Nasdaq Capital Market if compliance requirements are not maintained, decreasing liquidity and ability to raise capital.
• Results of preclinical studies and early clinical trials may not be predictive of late-stage success, and interim data may change.
• Delays in patient enrollment for clinical trials could delay or prevent regulatory approvals.
• Even if approved, emavusertib may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Expending limited resources on a particular drug candidate or indication may lead to missing more profitable opportunities.
• Lack of sales, marketing, or distribution experience, requiring building infrastructure or relying on third parties, which carries risks.
• Dependence on third parties to produce emavusertib, with risks of manufacturing delays, compliance problems, or high costs.
• Reliance on a limited number of suppliers for raw materials, leading to potential delays, shortages, or contamination.
• Dependence on companion drugs (ibrutinib, zanubrutinib) for clinical trials; supply issues could cause significant delays.
• Risks related to the enforcement of intellectual property rights and confidentiality in China and India.
• Loss of license rights to intellectual property that is important to the business.
• Potential claims that employees have wrongfully used or disclosed trade secrets of former employers.
• Regulatory authorities have substantial discretion, and varying interpretations of data could delay, limit, or prevent marketing approval.
• Failure to obtain marketing approval in foreign jurisdictions would prevent emavusertib from being marketed abroad.
• Orphan drug designation and exclusivity may not prevent the FDA or EMA from approving competing products.
• Ongoing regulation and potential for restrictions or withdrawal from the market if marketing approval is obtained, with substantial penalties for non-compliance.
• Uncertainty and potential delays from accelerated development pathways (e.g., FDORA, Project Optimus).
• Requirement to obtain clearance or approval of a companion diagnostic, which could delay or impair revenue generation.
• Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, and government shutdowns could hinder timely guidance and approvals.
• Approval of generic versions of small molecule investigational products or insufficient exclusivity periods could adversely affect sales.
• Current and future legislation may increase the difficulty and cost of obtaining reimbursement for drug candidates.
• Subject to U.S. and foreign anti-corruption and anti-money laundering laws, with non-compliance leading to criminal/civil liability.
• Subject to governmental export and import controls, potentially impairing international market competition.
• Changes in and uncertainty surrounding U.S. trade policy and international trade policies, particularly with respect to China, could impact business.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Employee misconduct or internal computer system failures/security breaches could disrupt product development.
• Stock price volatility, potential dilution from future stock sales, and anti-takeover defenses could affect shareholder value.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future and will require substantial additional funding to advance emavusertib through regulatory approval and commercialization. It plans to seek additional funding through private or public equity financings, collaborations, or other strategic transactions. Initial data from the TakeAim CLL study is anticipated in the fourth quarter of 2026. The company also intends to continue development of emavusertib in AML, contingent on securing additional funding. The regulatory landscape, particularly in the EU, is undergoing significant changes with the new Pharma Package expected to be adopted by mid-2026 and take effect mid-2028, potentially impacting regulatory exclusivity periods.

Management Comments

• "We are focusing our operations on our ongoing combination Phase 1/2 study in relapsed/refractory PCNSL with ibrutinib and our recently initiated Phase 2 combination study of emavusertib in CLL with zanubrutinib."
• "Our monotherapy and combination studies of emavusertib in AML are substantially complete, with additional funding, we plan to continue development of emavusertib in AML."
• "We will require substantial additional funding to fund the development of emavusertib through regulatory approval and commercialization, and to support our continued operations."
• "We have faced and expect to continue to face substantial difficulties in raising capital."
• "If sufficient funds are not available, we will have to delay, reduce the scope of, or eliminate our research and development program for emavusertib..."
• "We may seek to engage in one or more strategic alternatives, such as a strategic partnership with one or more parties, the licensing, sale or divestiture of some of our assets or proprietary technologies or the sale of our company, but there can be no assurance that we would be able to enter into such a transaction or transactions on a timely basis or on terms favorable to us, or at all."
• "If we are unable to obtain sufficient capital, we would be unable to fund our operations and may be required to evaluate alternatives, which could include dissolving and liquidating our assets or seeking protection under the bankruptcy laws..."

Industry Context

StockSavvy.ai notes that the biotechnology sector, particularly oncology drug development, is characterized by intense competition, high R&D costs, and significant regulatory hurdles. The company's reliance on external financing and collaborations is typical for early-stage biotech firms. The recent changes in U.S. and EU pharmaceutical pricing and regulatory policies (e.g., IRA, new Pharma Package, FDORA, Project Optimus) create a challenging and uncertain environment for drug commercialization and reimbursement, potentially impacting future revenue streams and market access. The focus on accelerated approval pathways for serious conditions like PCNSL and CLL reflects an industry trend to expedite therapies for unmet medical needs, though these pathways come with their own stringent requirements and post-market obligations.

Comparison to Industry Standards

• The company's accumulated deficit of $1.2 billion and recurring losses are common for biotechnology companies in the research and development phase, as drug development is capital-intensive and lengthy.
• The reliance on equity financings and strategic collaborations (like with Aurigene) is a standard funding model for biotech firms without commercialized products, similar to how many smaller biotechs operate to de-risk and fund their pipelines.
• The pursuit of Orphan Drug Designation for rare conditions like PCNSL, AML, and MDS is a common strategy to gain market exclusivity and regulatory incentives, aligning with industry practices for developing therapies for unmet needs.
• The discussions with CHMP and FDA for accelerated approval pathways (CMA, Accelerated Approval) for emavusertib in PCNSL are consistent with industry efforts to expedite market access for promising oncology candidates, similar to approaches taken by companies like Gilead Sciences (axicabtagene ciloleucel) or Astellas Pharma (gilteritinib) for other cancer indications.
• The competitive landscape in IRAK4, FLT3, CLL, and PCNSL, with numerous large pharmaceutical and specialized biotechnology firms (e.g., Rigel, AstraZeneca, AbbVie, Johnson & Johnson, Eli Lilly, Novartis, Gilead, Ono, Astellas, Daiichi Sankyo), indicates that the company operates in a highly competitive environment, typical for oncology.
• The sale of Erivedge royalty rights to Oberland Capital Management, LLC, is a common non-dilutive financing strategy for biotech companies to monetize future revenue streams from approved products, similar to royalty monetization deals seen across the industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal proceedings.

Related Party Transactions

• In November 2025, the company sold its 100% interest in Curis Royalty to TPC Investments Royalty LLC, a limited liability company managed by Oberland Capital Management, LLC. This is a related party transaction as Oberland Capital Management, LLC was also involved in the original royalty interest purchase agreement in March 2019.

Stakeholder Impact

• Shareholders face significant dilution risk from past and future equity financings, potential for further stock price volatility, and the risk of losing all or part of their investment if the company cannot continue as a going concern. Anti-takeover provisions may limit their ability to influence management or approve favorable acquisition transactions.
• Employees' continued employment and the value of their stock-based compensation depend on the company's ability to secure funding and advance drug development. The recent RIF at HHS and FDA could impact regulatory processes, indirectly affecting employees.
• Future customers (patients) could benefit from new treatment options for PCNSL and CLL if emavusertib is successfully developed and commercialized, addressing unmet medical needs.
• Suppliers and creditors face increased risk of non-payment if the company's financial condition deteriorates and it cannot secure additional funding or is forced into liquidation/bankruptcy.

Next Steps

• Initiate dosing in the TakeAim CLL study during the first half of 2026.
• Expect initial data from the TakeAim CLL study in the fourth quarter of 2026.
• Continue discussions with CHMP and FDA to align on confirmatory study design for emavusertib in PCNSL.
• Plan to continue development of emavusertib in AML with additional funding.
• Seek additional funding through private or public equity financings, collaborations, or other strategic transactions.
• Evaluate strategic alternatives if unable to obtain sufficient capital, including dissolving and liquidating assets or seeking bankruptcy protection.
• The 2026 Incentive Plan was approved by stockholders in March 2026.
• The new EU Pharma Package legislation is expected to be adopted by mid-2026 and take effect mid-2028.
• Section 122 tariffs are set to expire on July 24, 2026, absent extension.
• CMS proposed GLOBE and GUARD pilot programs are proposed to go into effect beginning October 1, 2026.
• The next PDUFA reauthorization must be enacted by October 1, 2027.
• Negotiated prices for the second set of 15 Medicare drugs become effective on January 1, 2027.
• Negotiated prices for the third set of 15 Medicare drugs become effective on January 1, 2028.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about our ability to continue as a going concern' and will require 'substantial additional funding' to continue operations and drug development. While a recent PIPE financing provided $18.6 million, this is insufficient for long-term needs. The sale of the Erivedge royalty stream eliminates a previous source of revenue, increasing reliance on uncertain future financings and clinical success. The high accumulated deficit, continued operating losses, intense competition, and significant regulatory risks create an extremely high-risk investment profile. The explicit risk of liquidation or bankruptcy makes the stock a strong sell for a seasoned investor.

Keywords

Emavusertib, IRAK4 inhibitor, FLT3 inhibitor, PCNSL, CLL, AML, Orphan Drug Designation, Clinical Trials, Biotechnology, Oncology, Drug Development, SEC Filing, Going Concern, Capital Raise, Nasdaq